luspatercept: Clinical Trials

12 trials of luspatercept, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 active not recruiting, 4 not yet recruiting, 2 completed, 1 recruiting. 12 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	12	Active not recruiting 5, Not yet recruiting 4, Completed 2, Recruiting 1
Phase 2	2	Not yet recruiting 2

Follow luspatercept: new trials by email Literature Review of luspatercept trials Research Report on luspatercept

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes Luspatercept - Myelodysplastic Syndromes	Phase 3	Not yet recruiting	Institute of Hematology & Blood Diseases Hospital, China	75	2026-10-31	2026-10-26
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies Luspatercept, Epoetin - Luspatercept, Epoetin	Phase 2 / Phase 3	Not yet recruiting	Nanfang Hospital, Southern Medical University	90	2026-06-15	2026-06-09
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment	Phase 2 / Phase 3	Not yet recruiting	Nanfang Hospital, Southern Medical University	196	2026-05-01	2026-04-20
AZA+Lus VS AZA Monotherapy in HR-MDS Azacitidine (AZA), Luspatercept - Higher-risk Myelodysplastic Syndrome	Phase 3	Not yet recruiting	Peking Union Medical College Hospital	86	2025-04-01	2025-04-15
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes	Phase 3	Active not recruiting	Bristol-Myers Squibb	402	2023-10-24	2026-06-30
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants Luspatercept - Myelodysplastic Syndromes	Phase 3	Active not recruiting	Bristol-Myers Squibb	106	2023-10-05	2026-06-15
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. Luspatercept - Myelodysplastic Syndromes	Phase 3	Active not recruiting	GWT-TUD GmbH	70	2021-10-27	2025-09-30
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions ACE-536, Placebo - Myeloproliferative Disorders, Myelofibrosis	Phase 3	Active not recruiting	Celgene	313	2021-02-25	2026-07-16
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials Luspatercept - Myelodysplastic Syndromes (MDS), Beta-thalassemia	Phase 3	Recruiting	Celgene	665	2019-08-12	2026-07-01
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve Luspatercept, Epoetin alfa - Myelodysplastic Syndromes	Phase 3	Active not recruiting	Celgene	363	2019-01-02	2024-11-20
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia Luspatercept, Placebo - Erythrocyte Transfusion, Beta-Thalassemia	Phase 3	Completed	Celgene	336	2016-05-02	2023-04-18
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Luspatercept, Placebo - Myelodysplastic Syndromes	Phase 3	Completed	Celgene	229	2016-02-09	2021-12-17

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding